CALCA and migraine disorder: Building on the initial observations of elevated CGRP in response to trigeminovascular activation in human and preclinical studies as well as during migraine attacks [10, 14], it has become apparent that CGRP release is a key target for migraine therapies, including the established triptan compounds [100, 101].